大会期间，平谷区副区长彭石发布了《农业中关村核心区发展2.0》，提出以合成生物、智慧农业为重 点，打造全国农业科创中心。"作为北京农业中关村核心区，平谷始终以科技创新为核心驱动力，在合 成生物、关键技术转化、企业集聚等领域取得了一批标志性成果。"他表示，合成生物创新中心将建成 中试生产线及AI生物设计自动化平台。关键技术转化方面，平谷已实现从"实验室"到"田间地头"的高效 贯通，自主研发的蛋鸡DNA芯片"凤芯壹号"打破国外垄断，沃德系列白羽肉鸡品种填补国内空白，基 因编辑抗蓝耳病猪实现100%抗病；华北地区最大的815亩智能温室集群即将投入使用，集成无人机协同 作业、环境智能感知等技术，亩均产量较传统种植提升3倍以上。 据悉，本次大会将持续至10月15日，其间将以南南合作、科技赋能女性、设施农业、消除贫困饥饿、农 业保险、可持续金融、可控农业、智慧养殖、粮食减损、爬行动物、土地经营权流转等为主题，举办十 余场专题会议、平行会议，以及中非农业科技合作等国际交流活动。 新京报讯（记者曹晶瑞）2025世界农业科技创新大会正在召开，新京报记者获悉，本次大会共吸引了来 自90余个国家和地区的近800位涉农领域科学家、高 ...

北京商报讯（记者 吴其芸）10月13日，2025世界农业科技创新大会（WAFI）在北京平谷金海湖国际会展中心开幕，将持续至10月15日。大会以"践行大食 物观，共建韧性食物供应体系"为主题，来自90余个国家和地区的近800位涉农领域科学家、高校校长、教育家、企业家、优秀青年代表参会，共话农业科技 发展趋势，共探农食行业挑战与发展路径。 值得关注的是，大会创新推出公益林、低碳跑、田间展、农食汇、青年大赛等多元活动，让与会嘉宾感受到农业创新的温度，在沉浸式场景里看见农业可持 续未来。 据平谷区副区长彭石介绍，作为北京农业中关村核心区，平谷始终以科技创新为核心驱动力，在合成生物、关键技术转化、企业集聚等领域取得了一批标志 性成果，这些进展既是大会落地的重要基础，更是服务首都和全国农业发展的关键支撑。目前，平谷已集聚首农、拜耳、博瑞迪等多家涉农企业，通过117 个"博士农场"吸引411名博士落地，推动超百项成果转化。"未来，我们将以本次农业科技创新大会为契机，持续深化创新，打造全国农业科创中心。" 自2023年首届大会举办以来，WAFI已在全球范围内形成广泛影响力，跃升为世界农业领域的顶级盛会之一，并取得显著的转化成 ...

Core Insights - Elevit, a leading brand in the prenatal folic acid market, is attempting to extend its brand trust into the children's health sector by launching an eye care product aimed at children over three years old [1][3][6] - The product, priced at 269 yuan for 32 pieces, is significantly higher than most competitors, but it currently ranks 23rd in sales on major e-commerce platforms, indicating a substantial gap in market performance compared to leading brands [1][5][7] Product Launch and Market Positioning - Elevit has introduced a children's eye care product that emphasizes three main features: sugar-free, innovative Lifechews formulation for better absorption, and scientifically blended lutein [4][9] - The product is positioned as a high-end offering, with a single piece priced at approximately 8.41 yuan, which is notably higher than competitors like Inne and Swisse [9] Competitive Landscape - Elevit faces stiff competition from established children's nutrition brands such as Inne and Little Umbrella, as well as well-known domestic brands like Xing Sha and Yi Ke Xin, which have a stronger foothold in the children's market [6][7] - The children's nutrition market is experiencing growth, with global market size projected to increase from $110.99 billion in 2019 to $136.38 billion in 2024, indicating potential opportunities for Elevit [7] Challenges and Consumer Perception - Elevit’s current product line for children is limited, lacking a comprehensive range to meet parents' one-stop shopping needs, which may hinder its ability to compete effectively [6][8] - The brand's high pricing strategy may not be supported by sufficient market data or consumer feedback, making it challenging to attract buyers who prioritize established brands [8][9]

Core Insights - The 2025 World Agricultural Technology Innovation Conference opened in Beijing, focusing on building resilient food supply systems amid global challenges such as climate change and population growth [1][2] - China, utilizing about 9% of the world's arable land and 6% of freshwater resources, supports nearly 20% of the global population, emphasizing the importance of technological innovation in agriculture [1] - The conference highlighted China's commitment to agricultural research and innovation, showcasing initiatives like the "Agricultural Zhongguancun" development plan and the Shennong Model 3.0 [1][2] Group 1 - The conference gathered nearly 800 participants from over 90 countries, discussing themes like South-South cooperation and smart agriculture [1] - Experts emphasized that building a secure and stable resilient food supply system is crucial for global food security and sustainable development [1] - China is transforming its agricultural production towards ecological, intelligent, and industrial models through various strategies, including collaborative research and technological breeding [1] Group 2 - Beijing's Pinggu District has become a hub for agricultural innovation, attracting major companies and experts to enhance agricultural technology and practices [2] - The district has established 117 "Doctor Farms," attracting 411 agricultural experts to facilitate the transformation of over 100 research outcomes [2] - Foreign guests expressed interest in deeper collaboration with Chinese experts in modern seed industry, smart agriculture, and the integration of industry and academia [2]

Core Viewpoint - Elevit, a leading brand in the prenatal folic acid market, is attempting to extend its brand trust built during pregnancy into the children's health sector by launching an eye care product for children aged 3 and above, entering the lutein market [1]. Company Summary - Elevit has introduced a children's eye care product priced at 269 yuan for a box of 32 pieces, which is significantly higher than most competitors [1][13]. - The product currently ranks 23rd on JD's "Hot Selling Baby Lutein" list, indicating a substantial gap in sales compared to leading brands [1][10]. - Elevit has also promoted liquid calcium for infants and young children since last year, marking its transition from a prenatal nutrition brand to a new entrant in the children's market [1][8]. Product Characteristics - The children's eye care product emphasizes three main features: sugar-free, innovative Lifechews® formulation that enhances absorption efficiency, and scientifically formulated lutein [8]. - The product is marketed as a dietary supplement rather than a medicine or health product, as it has not received the "blue hat" certification [7][8]. Market Position and Challenges - Elevit benefits from established brand trust in prenatal nutrition, which could facilitate its entry into the children's market [9]. - However, the brand faces challenges in converting its prenatal advantages into competitiveness in the children's sector, especially against brands like inne and LittleUmbrella that specialize in children's nutrition [9][10]. - The current product line is limited, lacking a comprehensive range to meet parents' one-stop shopping needs, which is a significant disadvantage compared to competitors [9][10]. Market Context - The children's nutrition market is in a growth phase, with global market size expected to increase from $110.99 billion in 2019 to $136.38 billion in 2024 [10]. - Lutein has seen significant growth, with a 20% year-on-year increase in sales volume on major e-commerce platforms in Q1 2024 [10]. Pricing Strategy - Elevit's eye care product is positioned as a premium offering, with a per-unit price of approximately 8.41 yuan, which is notably higher than competitors [13]. - The product claims to enhance absorption through its patented formulation, but consumer understanding of such technical claims may be limited [13].

作为上海生物医药产业的"链主"企业，上海医药已经连续6年入选了财富世界500强榜单，2024年实现了营业收入2752.51亿元，跑出了发展加速 度。 在上海医药执行董事、总裁沈波看来，生物医药全链条创新突破，将成为行业的发展主线。加强前沿领域源头创新和关键核心技术的攻关，抢占 产业发展的制高点，强化产业链的自主可控，将成为未来发展的重要方向。 生物医药创新如何更快落地？产业如何更强链接？资本如何更好赋能？记者从10月11日召开的第八届浦江医药健康产融创新发展峰会（以下简称 浦江峰会）上获悉，上海将持续加大政策供给，汇聚各方力量，全力推动基础研究、孵化转化、临床试验、审评、审批落地生产推广应用的全链 条加速，加快建设世界级生物医药创新高地和产业集群。 作为上海国际生物医药产业周的重要组成部分，浦江峰会已成为引领中国医药健康产业发展的创新风向标，亦是汇聚全球智慧、促进产学研深度 融合的高端学术平台。 本届峰会由上实集团、中国医药企业管理协会指导，上海医药主办，上海前沿承办，汇聚了来自政、产、学、研、资的300余位参会嘉宾，线上参 与人数超万人，共绘医药健康产业的未来蓝图。 上海市科委副主任黄红介绍，生物医药产业是 ...

2024年以来草甘膦价格始终维持低位，于2025年3月触及2.31万元(吨价，下同)的阶段性低点，随后开启 修复行情。截至9月21日，95%含量草甘膦报价已回升至2.75万元左右，97%含量草甘膦报价达到2.8万 元。首创证券分析师翟绪丽预计，草甘膦市场的景气度正逐渐回暖。 产能增量有限推涨价格 从国内市场结构来看，目前国内草甘膦市场70%～80%消费依赖出口。2024年，我国其他非卤化有机磷 衍生物，主要是草甘膦出口数量为60.2万吨，同比增长30.6%；2025年1至5月，我国其他非卤化有机磷 衍生物出口数量为27.2万吨，同比增长13.3%。 据观研天下发布的《中国草甘膦行业发展趋势研究与投资前景分析报告(2025—2032年)》，目前全球草 甘膦总产能为118万吨/年，其中拜耳以37万吨/年的产能居第一，剩余81万吨/年产能全部集中在中国， 主要分布于兴发集团、福华化学、新安股份、江山股份等企业。 长城证券分析师肖亚平认为，拜耳的草甘膦产能存在不确定性，且海外草甘膦产能同样呈现"只减不 增"的态势。 在中农纵横研究员吴江看来，草甘膦价格变动周期的驱动因素虽不尽相同，但总体而言，供给侧对价格 的影响权重 ...

Group 1 - The U.S. will impose a 100% tariff on all imported brand and patented drugs starting October 1, directly impacting the European pharmaceutical industry [1] - 73% of brand drugs in the U.S. are sourced from European countries like Ireland, Germany, and Switzerland, with Ireland's drug exports to the U.S. projected to reach €44.4 billion in 2024, accounting for over 60% of Europe's exports to the U.S. [1] - Germany's pharmaceutical exports to the U.S. are expected to exceed €27 billion in 2024, representing about one-quarter of Germany's total pharmaceutical exports [1] Group 2 - German and European pharmaceutical industry associations warn that U.S. tariffs will severely impact the pharmaceutical sector and negatively affect U.S.-Europe trade relations [2] - Bayer's CEO warns that sustained high tariffs will weaken pharmaceutical companies' operational and R&D capabilities, jeopardizing innovation and competitiveness [2] - The American Pharmacists Association indicates that tariffs could lead to a 30% to 50% increase in prices for commonly used patented drugs, disrupting international supply chains and affecting drug availability [2] Group 3 - Despite large investment plans from multinational pharmaceutical companies, industry insiders argue that returning production to the U.S. may do more harm than good, as tariffs could disrupt existing pharmaceutical supply chains [3] - The U.S. government's imposition of tariffs is seen as a violation of market development principles, likely distorting the industry chain and increasing production costs while reducing efficiency [3]

Group 1 - The eighth China International Import Expo (CIIE) has over 3,200 enterprises from more than 110 countries and regions confirmed to participate, with a signed exhibition area exceeding 360,000 square meters, reflecting strong confidence in the Chinese market [1] - Medtronic has transformed over 30 flagship products into commercial offerings over the past seven years, showcasing a strategic upgrade from exhibitor to investor, highlighting the transition of innovation from "imported" to "exported" [1] - Bayer will showcase 26 highlight exhibits on an 800-square-meter double booth, and its third regenerative agriculture demonstration farm in China will debut at the expo, emphasizing collaboration in biobreeding and regenerative agriculture [1] Group 2 - The CEO of Kasy Group emphasized that the expo serves as an important open platform for multinational companies to deepen cooperation and achieve results, expressing anticipation for collaboration with Chinese partners [2] - Shanghai is enhancing the convenience of participation in the eighth CIIE through innovative measures, with a leadership group overseeing 264 key tasks to ensure smooth operations [2] - A policy package has been formed to support exhibitors, covering various departments such as commerce, taxation, and customs, including initiatives like immediate tax refunds for departing visitors and facilitation of customs clearance [2]

Group 1: Core Insights - The 8th China International Import Expo (CIIE) is approaching, with companies like Kao and Bayer showcasing their innovations and commitment to the Chinese market [1][2][3] - Kao has localized production for several brands, including Freeplus and Curel, and aims to respond quickly to market changes by moving its global headquarters for Freeplus to China [1][2] - Bayer will present approximately 26 highlight exhibits, including 5 global debuts and 8 China debuts, focusing on innovations in pharmaceuticals, consumer health, and crop science [3][4] Group 2: Company Strategies - Kao's participation emphasizes a "global innovation + local implementation" model, adapting products to meet local agricultural needs and consumer preferences [1][2] - Bayer's strategy includes showcasing advancements in oncology, cardiovascular health, and agricultural innovations, with a focus on integrating global knowledge into local agricultural development [3][4] - Both companies are leveraging the CIIE as a strategic platform to connect with the Chinese market and enhance their brand presence [2][4]